Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (June 2026)
23 slides from Island Pharmaceuticals's investor presentation, Jun 11, 2026
Slide 1: Investor presentation
11 June 2026 ASX Announcement Investor presentation MELBOURNE Australia, 11 June 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to provide the following presentation which will be used at the Gold Coast Investment Showcase
Slide 2: Island (ASX: ILA) is focused on areas of unmet need
Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir. ISLA-101 has a well-established safety profile, being repurposed
Slide 3: Combatting Urgent Viral Disease Threats
COMBATTING URGENT VIRAL DISEASE THREATS Advancing Galidesivir as a multi -filovirus countermeasure under the FDA Animal Rule D r D a v id Fo s t e r, CEO & Ma n a g in g D ire c t o r | Mr J a s o n Ca rro ll, No n -Exe c u t iv e Ch a irm a n June 2026 ASX: ILA
Slide 4: Disclaimer
Disclaimer Important Information This disclaimer applies to this presentation and the information contained in it (Presentation). By reading this disclaimer you agree to be bound by it. The Presentation has been prepared by Island Pharmaceuticals Limited and all related bodies corporate (Company). C
Slide 5: Island Pharmaceuticals (ASX: ILA)
ISLAND PHARMACEUTICALS (ASX: ILA) TARGETING INFECTIOUS DISEASES TWO PROGRAMS Phase 2a/b PROTECT clinical trial in dengue Two, well advanced clinical stage programs complete FDA Animal Rule pathway actively Major market potential via both programs advancing through new USAMRIID CRADA Multiple near te
Slide 6: Company Overview
Company Overview Shares on issue¹: 295,916,682 Substantial shareholders Price per share¹: $0.365 Dr William James Garner³ 15.50% Market capitalisation¹: $108.1m Cash at bank (31 March 2026)²: $14.2m Jason Alan Carroll³ 11.92% Potential additional capital from vested options where MWP Partners Limite
Slide 7: Company Overview
Company Overview Two clinical stage assets – Galidesivirand ISLA -101 - both with Priority Review Voucher potential based on approval Galidesivir: ￭ Small molecule with broad antiviral activity against numerous high-priority threats ￭ Robust development history with over US$70m in funding to-date fr
Slide 8: The Filovirus Threat Landscape
The Filovirus Threat Landscape AN URGENT AND GROWING GLOBAL SECURITY CHALLENGE Extremely high fatality rates: Marburg up to 88%, Ebola up to 90%, Sudan up to 47%, Bundibugyo –50%30 Limited BSL-4 pathogens: Bioterror relevance: Current situation: countermeasures:No Require maximum Historical Ongoing
Slide 9: The Preparedness Gap
The Preparedness Gap THERE ARE NO FILOVIRUS THERAPEUTICS CAPABLE -STRAIN OF CROSS PROTECTION Existing Ebola countermeasures No approved therapeutics for are strain-specific (Zaire only) Marburg, Bundibugyo or Sudan virus Outbreaks increasingly involve Stockpile lacks a broad-acting rare or divergent
Slide 10: Why Galidesivir?
Why Galidesivir? A BROAD -ACTING ANTIVIRAL WITH STRONG FILOVIRUS EFFICACY -ALIGNED AND FDAPATHWAY Demonstrated multi-filovirus activity IV and IM formulations with favorable (Marburg, Ebola, Sudan) safety profile Strong in vivo efficacy with delayed Manufacturing route improved with 2– dosing 3X yie
Slide 11: Galidesivir Competitive Advantage
Galidesivir Competitive Advantage FEATURE GALIDESIVIR OBELDESIVIR REMDESIVIR MAFTIVIMAB MBP134 CHADOX1 -BDBV RVSV -BDBV-GP MRNA-LNP BDBV BROADEST SPECTRUM ANTIVIRAL ACTIVITY (FILOVIRUSES AND OTHER FAMILIES) PEP AND TX FLEXIBILITY (IM/IV) ROOM TEMP STABLE SMALL MOLECULE PHASE 1 HUMAN SAFETY DATA Isla
Slide 12: Marburg NHP Survival
MARBURG NHP SURVIVAL 94% survival in Marburg NHP Model with treatment initiated up to 48 hours post -infection This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports imalAn Rule advancement Island Pharmaceuticals Limited 09
Slide 13: Ebola NHP Survival
EBOLA NHP SURVIVAL Robust efficacy in Ebola NHP model with delayed dosing Survival of rhesus non-human primates challenged with Ebola virus following intramuscular administration of 100 mg/kg BID loading dose followed by 25 mg/kg BID for 10 days. Percentage survival 100% survival when treatment comm
Slide 14: FDA alignment significantly de-risks regulatory pathway
FDA alignment significantly de -risks regulatory pathway Island has the potential to become to first Australian company to gain drug approval via the FDA’s Animal Rule FDA confirmed the Clear guidance provided FDA advised that CRADA secured with Animal Rule pathway on clinical program Galidesivir wo
Slide 15: An Established Regulatory Pathway
An Established Regulatory Pathway 4~8 YEARS 4~6 YEARS 1 YEAR In vivo Basic Drug Experiment experiments Phase 1 Phase 2 Phase 3 NDA study design in vitro (animal clinical trials clinical trials clinical trials studies) In vivo Pivotal Basic Drug Experiment experiments efficacy Animal Rule NDA study d
Slide 16: Expanded CRADA with USAMRIID
Expanded CRADA with USAMRIID Agreement with US Army Medical Research Institute of Infectious Diseases and the Geneva Foundation to secured - 23 non human primates and advance dose optimisation study USAMRIID is the US Amended CRADA Dose optimisation study Study to evaluate high Army’s premier resear
Slide 17: NHP dose optimisation protocol
NHP dose optimisation protocol GALDESIVIR ADMINISTRATION (HR DISEASE BIOMARKER PK SPECIMEN STUDY GROUP # ANIMALS GALDESIVIR DOSE DOSING FREQUENCY ENDPOINTS POST VIRUS SPECIMEN COLLECTION COLLECTION EXPOSURE) 0 MG/KG (VEHICLE 1 4 CONTROL - 30MIN 24 HOURS BID INFUSION) 15 MG/KG (30MIN CLINICAL 2 4 24
Slide 18: Recent appointments strengthen clinical development
Recent appointments strengthen clinical development Combining deep Galidesivir expertise with extensive US biodefence and procurement experience to accelerate development, funding and commercialisation opportunities Mark Herzog– Senior Global Health Security Advisor Raymond Taylor– Senior Scientific
Slide 19: Current Ebola outbreak highlights the opportunity
Current Ebola outbreak highlights the opportunity Emerging filovirus outbreaks continue to reinforce the importance of preparedness, rapid response capability and effective medical countermeasures Governments continue to prioritise Active Ebola outbreak in East Africa: Limited treatment options avai
Slide 20: Supply chain optimised to meet pending demand
Supply chain optimised to meet pending demand Critical manufacturing and quality infrastructure being established to support FDA submission and future procurement opportunities Manufacturing campaign commenced: • Agreement with PI Health Sciences for a 5kg GMP • GMP-grade Galidesivir to be delivered
Slide 21: Multiple commercialisation opportunities
Multiple commercialisation opportunities Galidesivir has the potential to fill multiple gaps in the US government’s biodefence stockpile Non-human primate PRV Eligible for first Strategic National Virus Cell culture data Animal data Animal Rule Potentia efficacy indication Stockpile Potential Marbur
Slide 22: Animal Rule is a proven path for SNS inclusion
Animal Rule is a proven path for SNS inclusion Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS) In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contract and have generated ‘lifetime sal
Slide 23: Island Pharmaceuticals
Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — Investor Presentation (June 2026) on 6ix